CJC-1295 NO DAC 10 mg| NeuroPept Labs

Description

CJC-1295 No DAC also known as Modified GRF (1-29) or Mod GRF 1-29 is a synthetic, tetrasubstituted analogue designed to resist enzymatic degradation while maintaining high-affinity binding to the receptor in the anterior pituitary. Unlike its DAC-modified counterpart, CJC-1295 No DAC lacks the albumin-binding Drug Affinity Complex (DAC) modification, resulting in a pharmacokinetic profile that closely mimics the physiological, pulsatile pattern of endogenous secretion.

NeuroPept Labs supplies CJC-1295 No DAC 10mg as a research-grade lyophilized peptide intended strictly for in vitro laboratory and analytical research use. All batches are synthesised under controlled conditions and verified through third-party analytical testing. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code found in the product images.

Mechanism of Action (Research Overview)

CJC-1295 No DAC retains the core  receptor binding sequence with four amino acid substitutions that confer resistance to DPP-IV-mediated cleavage and improve metabolic stability. Upon binding on anterior pituitary somatotrophs, it activates Gs/adenylyl cyclase signalling, increasing intracellular cAMP and triggering acute, pulsatile secretion.

• No albumin binding  absence of DAC modification means no prolonged plasma retention; ideal for acute-response and combination research protocols
• DPP-IV resistance tetrasubstitution modifications protect against rapid enzymatic degradation seen with native (~7-10 minute half-life)
• Half-life (~30 minutes) substantially extended compared to native while maintaining pulsatile pharmacokinetics

CJC-1295 No DAC is frequently studied alongside Ipamorelin a  ghrelin receptor agonist as complementary and activation has been shown to produce additive effects on pulsatile secretion in research models.

CJC-1295 No DAC vs CJC-1295 With DAC

Research Applications

• Neuroendocrine axis studies  receptor binding kinetics and acute somatotroph signalling
• Pulsatile  secretion modelling replicating physiological ultradian  rhythms in preclinical models
• Combination peptide research dual-pathway  stimulation studies with Ipamorelin
• IGF-1 downstream pathway research stimulated hepatic IGF-1 production and anabolic signalling
• Short-duration in vitro and ex vivo experiments where compound half-life must be controlled and limited
• Structure-activity relationship studies evaluating how tetrasubstitution modifications affect affinity and selectivity

Product Specifications

Storage and Handling

• Store lyophilized peptide at -20°C or below prior to reconstitution
• Avoid repeated freeze-thaw cycles
• Protect from direct light, humidity, and room temperature exposure
• Reconstitute using sterile laboratory solvents under aseptic conditions
• Once reconstituted, store at 4°C and use within recommended timeframes

Scientific References

1. Prolonged Stimulation of GH and IGF-1 by CJC-1295 PubMed 2006
2. CJC-1295 With DAC vs CJC-1295 No DAC: Research Comparison Palmetto Peptides 2026

Research Use Disclaimer: All products sold by NeuroPept Labs are intended strictly for in vitro laboratory research and scientific investigation by qualified professionals. They are not approved for human consumption, medical treatment, or veterinary use. Purchasers are responsible for compliance with applicable regulations in their jurisdiction.